TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00298922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg tablets orally thrice weekly for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet orally thrice weekly for 24 weeks
Study: NCT02203708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Program for Mother with BPD (SuPMother-B).
Description: The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids.
Study: NCT04182763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
Study: NCT02307591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care + Amiodarone
Description: This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day
Study: NCT03670225

Intervention type: DEVICE
Group type: OTHER
Intervention: Invia Motion Endure
Description: NPWT Invia Motion Endure
Study: NCT00942617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 40 mg non-enteric coated ASA once daily for 21 + or - 2 days
Study: NCT01154478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet rich in omega-3 fatty acids
Description: fish at least 3 times per week, large leaf vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet rich in polyphenols
Description: extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet rich in omega-3 and polyphenols
Description: Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
Study: NCT04359771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow micro-pulse laser
Description: applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode micro-pulse laser
Description: applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
Study: NCT01498822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: 150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
Study: NCT03262558

Intervention type: OTHER
Intervention: No intervention
Description: Patients will undergo standard clinical routine practice in this indication
Study: NCT03843957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low touch Implementation Strategy
Description: Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low touch Implementation Strategy
Description: Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard

Intervention type: OTHER
Group type: OTHER
Intervention: low touch Implementation Strategy
Description: Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low touch Implementation Strategy
Description: Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard
Study: NCT00535522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-285 Dose Escalation Cohorts
Description: TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-285 Recommended Phase 2 Dosing Cohort
Description: Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
Study: NCT03393858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK Immunotherapy
Description: Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8EX
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
Study: NCT00774358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
Study: NCT04435613

Intervention type: OTHER
Group type: OTHER
Intervention: protective mechanical ventilation strategies
Description: 1. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
Study: NCT02507206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAR 0-100A
Description: 15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAR 0-100A
Description: 15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
Study: NCT01414465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Orlistat
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Orlistat
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
Study: NCT01088672

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical Thrombectomy
Description: The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
Study: NCT01235026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: 5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10\^10 CFU/g), twice a day, for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6g of maltodextrin, twice a day for 6 weeks.
Study: NCT01840150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breath test
Description: Undergo NA-NOSE breath test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01760915

Intervention type: OTHER
Intervention: NC100182 Hyperpolarized 3He
Description: Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.

Intervention type: OTHER
Intervention: NC100182 Hyperpolarized 3He
Description: Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.

Intervention type: OTHER
Intervention: NC100182 Hyperpolarized 3He
Description: Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
Study: NCT04434092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as specified in the respective arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crovalimab
Description: Crovalimab will be administered as specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as specified in the respective arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Eculizumab will be administered as specified in the respective arm.
Study: NCT02841306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Study: NCT02498522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: 83 patients will continue metformin until end of 1st trimester

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 83 patients will continue metformin until end of 1st trimester
Study: NCT01791283

Intervention type: PROCEDURE
Intervention: Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.
Study: NCT03463525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]osimertinib
Description: Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
Study: NCT03758365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate 0.05% Lotion
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Dipropionate 0.05% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 0.1% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study: NCT01366703

Intervention type: DEVICE
Intervention: implantable loop recorder Medtronic reveal XT Full view
Description: Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
Study: NCT03408509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
Study: NCT02033967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vasodilator induced hypovolemia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vasodilator induced hypovolemia
Study: NCT00507819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One placebo capsule will be taken by mouth three times-a-day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One placebo capsule will be taken by mouth three times-a-day.
Study: NCT02994225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery
Study: NCT00970840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-20gM or LNS-P&L
Description: Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P\&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
Study: NCT03140410

Intervention type: OTHER
Intervention: Antibiotic resistance
Description: Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated

Intervention type: OTHER
Intervention: Antibiotic resistance
Description: Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated
Study: NCT01421225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Insulin Pump therapy
Description: Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Insulin Pump therapy
Description: Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insulin Pump Therapy
Description: Subjects insulin doses followed their usual home routine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insulin Pump Therapy
Description: Subjects insulin doses followed their usual home routine.
Study: NCT03356080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: cytarabine, iv,15mg/m2 q12h, Day1-Day10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-transretinoic acid
Description: All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 300ug,sc,Day 0 until CR is achieved
Study: NCT00924495

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: rTMS therapy daily for two weeks, five times per week each lasting for half an hour

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: rTMS therapy daily for two weeks, five times per week each lasting for half an hour
Study: NCT01421628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness exercise program
Description: Exercise program, daily frequency, duration of 6 weeks.
Study: NCT04203641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-DOS47
Description: A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23
Study: NCT04563741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE!+UP
Description: behavioral weight management intervention developed for Veterans with PTSD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE!
Description: standard VA weight management intervention
Study: NCT03680586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo ultra low-dose radiation
Study: NCT00697125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine (208129)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine, experimental formulation
Description: Intramuscular injection, 3 doses